Governance and recurrence-prevention measures for Antimonopoly Act compliance
First written in FY2021. 2 of 3 entries say "Advanced", first in FY2023. Latest entry: FY2024-Q1.
The whole theme swung hardest in 2020: 2 of 7 companies on the "Worse" side.
7 other companies' latest entry also says "Advanced".
- FY2024-Q1AdvancedAnnual report
「In an organizational reform effective 1 April 2023, we reorganized the organization by establishing, among other units, the Group Medical Wholesale Business Headquarters, the Total Supply Chain Service Planning and Promotion Department, the Regenerative Medicine Business Planning and Development Office, and the Distribution Compliance Office. As an integrated group, we are working to strengthen the business model, create new value and reinforce our compliance framework.」
The Company established a Distribution Compliance Office, giving concrete organizational form to the strengthening of its compliance framework. - FY2023AdvancedAnnual report
「Alfresa Group has established and regularly convenes a subcommittee dedicated to compliance with the Antimonopoly Act within the Compliance and Risk Management Council's wholesale pharmaceuticals and related products business division. In addition to compliance departments and dedicated consultation services at each company, we have established a dedicated consultation service staffed by attorneys specializing in the Antimonopoly Act and strengthened dialogue with sales operations. As a control function, monitoring is conducted by the internal audit department and other bodies.」
The Antimonopoly Act recurrence-prevention measures took concrete form through specialized subcommittees, specialist departments at each Group company, dedicated internal and external consultation channels, specialist lawyers, and monitoring through internal audits. - FY2021First statedAnnual report
「Since undergoing an on-site inspection by the Japan Fair Trade Commission on 27 November 2019, the Group has worked to review and strengthen its compliance framework. In addition to introducing various systems and measures to strengthen governance, the Group has expanded Antimonopoly Act education and training for officers and is also working to enhance monitoring.」
In response to the suspicions of Antimonopoly Act violations and the indictments, the Group has systematically introduced recurrence-prevention measures throughout the Group, including restructuring its management framework, establishing directors responsible for compliance, setting up specialized subcommittees, issuing codes of conduct and establishing consultation channels, providing education and training, and monitoring through internal audits.